George Simon, MD, Named Executive Director of Moffitt Cancer Center- AdventHealth Joint Clinical Research Unit
George Simon, MD, joins Moffitt Cancer Center and AdventHealth as executive medical director of the joint Moffit Cancer Center-AdventHealth clinical research unit in Celebration. The new facility, opening in Fall of 2020, will provide access to the latest in cancer treatments through cutting-edge research, and access to investigational early phase clinical trials to patients in Central Florida.
Dr. Simon brings more than 20 years of clinical oncology translational research experience to this new role. Most recently, he served as section chief of translational research in the Department of Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center in Houston. Additionally, he served as medical director of the MD Anderson Cancer Network. He has also held director level positions at Hollings Cancer Center in Charleston, South Carolina, and Fox Chase Cancer Center in Philadelphia. Prior to that, Dr. Simon was a faculty member at Moffitt from 2000 to 2008 as director of mesothelioma research and a member of the Department of Thoracic Oncology.
In addition to his role at AdventHealth Celebration, Dr. Simon will also be a senior member of the Chemical Biology and Molecular Medicine Program at Moffitt. He specializes in lung cancer, mesothelioma and thymoma. In particular, he studies optimal strategies to deliver personalized cancer care in the form of either immunotherapy or targeted therapy individualized to a patient’s tumor molecular profile. He has served as principal investigator on numerous clinical trials and received several federal grants to support his work.
The new Moffit Cancer Center-AdventHealth clinical research unit, on the campus of AdventHealth Celebration, will have 28 chairs in the infusion center to provide standard-of-care therapies and 14 chairs in the clinical research unit, where investigational treatments will be administered. Care will be provided to patients with solid tumors or hematologic malignancies, such as leukemia. One clinical trial for lung cancer is already accruing patients at the location.
This new research center is part of a larger partnership between Moffitt and AdventHealth focused on enhancing both institutions’ ability to deliver the highest quality cancer care to patients. It includes innovative and leading-edge research activities at the AdventHealth Orlando and Celebration campuses, as well as a new Moffitt outpatient cancer center based in the community at AdventHealth Wesley Chapel.
For more information, visit here.